Shares of Japanese pharma major Daiichi Sankyo were down 5.3% at 4,226 yen today, after it announced that Japan Vaccine, its joint venture with GlaxoSmithKline, will be dissolved. 14 November 2018
Angion Biomedica and Sinovant Sciences have entered into a collaboration and license agreement for BB3, Angion's investigational small molecule mimetic of hepatocyte growth factor (HGF). 13 November 2018
Theravance Biopharma and Mylan have won US approval for Yupelri (revefenacin) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). 12 November 2018
German science and technology company Merck KGaA today signed an agreement with the Guangzhou Development District on innovation development in Southern China. 12 November 2018
Takeda Pharmaceutical has announced it will hold an extraordinary general meeting of shareholders to vote on its proposed acquisition of Shire on 5 December. 12 November 2018
AcelRx Pharmaceuticals today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. 9 November 2018
The European Commission has authorized an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which is marketed by UK pharma major GlaxoSmithKline. 9 November 2018
Japan’s Eisai has commenced full-scale operation of its new Suzhou, China-based plant. The facility is around five times larger than the former plant, and will be used to manufacture oral solid dose products. 8 November 2018
Takeda Pharmaceutical has launched Entyvio (vedolizumab) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan. 7 November 2018
Phase II data on cefiderocol (S-649266), a new drug from Japanese pharma company Shionogi for the treatment of urinary tract infection in patients at risk of multidrug-resistant Gram-negative infections, has appeared in The Lancet Infectious Diseases journal. 6 November 2018
Ireland-headquartered Theravance Biopharma announced the sale of its proprietary antibiotic, Vibativ (telavancin), to Cumberland Pharmaceuticals. 6 November 2018
Eli Lilly and NextCure have entered into a collaboration to discover new immuno-oncology therapies, utilizing NextCure's proprietary FIND-IO platform. 6 November 2018
German family-owned drugmaker Grünenthal has acquired additional global commercial rights for the dermal pain patch Qutenza (8% capsaicin) from USA-based Acorda Therapeutics. 5 November 2018
Swiss biotech Idorsia has maintained a collaboration with ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator under investigation for Duchenne Muscular Dystrophy. 5 November 2018
London’s Vertex Pharmaceuticals has won European approval for Symkevi (tezacaftor/ivacaftor) in combination with Kalydeco (ivacaftor) to treat certain people with cystic fibrosis (CF). 3 November 2018
US companies OvaScience and privately-held Millendo Therapeutics have updated the terms of their merger agreement – first announced in August - and increased the size of the associated financing, strengthening the position of the combined company. 2 November 2018
Johnson & Johnson has announced that the US Food and Drug Administration has approved Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular (CV) events due to a cardiovascular cause in certain people with type 2 diabetes. 1 November 2018
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024